InicioGRTSQ • OTCMKTS
add
Gritstone bio Inc
Cierre anterior
0,021 $
Intervalo diario
0,018 $ - 0,027 $
Intervalo anual
0,013 $ - 3,17 $
Cap. bursátil
2,84 M USD
Volumen medio
35,84 M
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
OTCMKTS
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | jun 2024info | Cambio interanual |
|---|---|---|
Ingresos | 921,00 mil | -52,89 % |
Gastos operativos | 7,70 M | 14,62 % |
Ingresos netos | -23,40 M | 33,64 % |
Margen de beneficio neto | -2,54 mil | -40,86 % |
Beneficios por acción | -0,16 | 48,39 % |
EBITDA | -25,98 M | 23,17 % |
Tipo impositivo efectivo | — | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | jun 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 55,71 M | -51,36 % |
Activos totales | 142,54 M | -35,97 % |
Responsabilidades totales | 120,35 M | 6,45 % |
Patrimonio total | 22,19 M | — |
Acciones en circulación | 118,11 M | — |
Precio-valor contable | 0,11 | — |
Rentabilidad económica | -49,31 % | — |
Retorno sobre capital | -57,02 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | jun 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | -23,40 M | 33,64 % |
Efectivo de operaciones | -26,81 M | 13,41 % |
Efectivo de inversión | -885,00 mil | -103,60 % |
Efectivo de financiación | 35,63 M | 3.403,74 % |
Variación neta del flujo de caja | 7,94 M | 248,24 % |
Flujo de caja libre | -14,40 M | 32,03 % |
Información sobre la empresa
Gritstone bio is a clinical-stage American biotechnology company which develops cancer and infectious disease immunotherapies and vaccines. It was founded in August 2015 as Gritstone Oncology, Inc., and is based in Emeryville, California.
In September 2021 it raised $55.0 million from the sale of 5,000,000 shares.
It started a Phase 1 trial of its self-amplifying mRNA second generation SARS-CoV-2 vaccine, GRT-R910, in the NIHCR Manchester Clinical Research Facility at Manchester Royal Infirmary, in September 2021. This is to explore the ability of GRT-R910 to boost and expand the immunogenicity of AstraZeneca's first-generation COVID-19 vaccine AZD1222 in healthy adults of more than 60 years. It uses lipid nanoparticles to deliver a broad set of antigens against SARS-CoV-2 that includes both stabilized spike protein and highly conserved viral protein regions containing T cell epitopes. Prof. Andrew Ustianowski is the study’s chief investigator.
On 10 November 2021, Gritstone announced positive preclinical data of its second-generation self-amplifying mRNA vaccine against SARS-CoV-2 in non-human primate models. Wikipedia
Fundación
ago 2015
Sitio web
Empleados
231
